Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 19:04:35·⟳ 抓取 19:05:05 +30s·⚡ 决策 10-25 21:28:46 +2h23m·1.9 天前
Genmab在ESMO 2026公布petosemtamab联合化疗治疗转移性结直肠癌II期随访更新：ORR 75%/67%
本条Investing.com报道与12:50 UTC已处理的GlobeNewswire公司通稿为同一具体催化（同一项NCT03526835 II期随访、同样75%/67% ORR、同样四项III期与周三投资者会），仅为AI生成的二手改写，无新增金额、指引修正、监管进展或III期数据；前案已判定II期单臂随访更新对Genmab大盘市值缺乏短线正期望，且无可交易合作方/跨市场映射。
📄 原文Investing.com↗ 原文
Genmab reports phase 2 trial data for colorectal cancer drug
5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX COPENHAGEN - Genmab A/S (NASDAQ:GMAB) announce…
不做 Genmab A/S（GMAB.US）
重复消息：本条Investing.com改写文与12:50 UTC已处理的GlobeNewswire公司通稿为同一II期随访催化，无任何新增事实；II期单臂数据非注册性读出、无PFS/OS，对大盘成熟biotech增量有限，下一实质催化为III期LiGeR读出与10/28投资者会，当前无短线正期望edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Genmab的petosemtamab II期mCRC随访更新数据积极但属渐进式巩固（单臂、无PFS/OS、III期仍在入组），且该催化的公司通稿约37分钟前已被处理为不做，本条Investing.com文章无新增事实，维持不做。
🔎 新鲜度:最早出现 2026-10-25 · 扩散 medium · price-in 风险 medium ↗
关键理由
- II期单臂随访更新非注册性读出，主要价值是为已在进行的四项III期提供安全性/缓解持续性背书，难独立驱动Genmab这类大盘成熟biotech重定价
主要风险
- 10月28日投资者更新会可能给出新的III期时间表或峰值销售指引，届时构成独立催化，需另行研判而非提前博弈
- petosemtamab输注反应率43-48%偏高，若后续III期安全性或缓解持续性恶化将削弱资产价值
先例如何影响了这次决策
对本次决策的影响:不影响结论——重复消息早停；前案基于催化性质（II期单臂随访、大盘biotech、无短线edge）的判断直接沿用
方向:未做外部先例统计：本条在跨源查重阶段即确认为同催化重复消息且无新增事实，按早停规则不再检索先例
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 261 ms
{"result": "search_processed_events:agent query=`genmab gmab petosemtamab bispecific antibody orr results | genmab petosemtamab phase 2 colorectal cancer esmo 2026 | petosemtamab mfolfox6 folfiri metastatic colorectal cancer data`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、3194 条本臂决策(完整)，返回 1 条候选。\n• 10-25
原文全文
展开原文 · 1,934 字
5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
COPENHAGEN - Genmab A/S (NASDAQ:GMAB) announced today updated results from a Phase 2 trial of petosemtamab, an investigational bispecific antibody, in combination with chemotherapy for metastatic colorectal cancer.
The trial evaluated 79 patients as of May 15, 2026, including 45 in first-line treatment and 34 in second-line treatment. According to a press release statement, confirmed and unconfirmed objective response rates were 75% in first-line patients and 67% in second-line patients at median follow-ups of 5.9 months and 7.1 months, respectively.
Among first-line patients with left-sided tumors, the objective response rate was 81%. Disease control rates were 95% in first-line patients and 93% in second-line patients.
The data was presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.
Petosemtamab-related treatment-emergent adverse events led to discontinuation in 2 of 42 patients receiving petosemtamab plus mFOLFOX6 and 1 of 37 patients receiving petosemtamab plus FOLFIRI. Infusion-related reactions occurred in 48% of patients receiving petosemtamab plus FOLFOX and 43% receiving petosemtamab plus FOLFIRI.
The trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had not previously received anti-EGFR therapy. Patients received 1,500 mg of petosemtamab every two weeks plus FOLFOX or FOLFIRI chemotherapy.
Genmab is conducting four Phase 3 trials of petosemtamab, including two in colorectal cancer and two in head and neck squamous cell carcinoma. The company will host an investor update on Wednesday.
Colorectal cancer is the third most commonly diagnosed cancer globally, with an estimated 1.9 million new cases annually, according to the World Health Organization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
COPENHAGEN - Genmab A/S (NASDAQ:GMAB) announced today updated results from a Phase 2 trial of petosemtamab, an investigational bispecific antibody, in combination with chemotherapy for metastatic colorectal cancer.
The trial evaluated 79 patients as of May 15, 2026, including 45 in first-line treatment and 34 in second-line treatment. According to a press release statement, confirmed and unconfirmed objective response rates were 75% in first-line patients and 67% in second-line patients at median follow-ups of 5.9 months and 7.1 months, respectively.
Among first-line patients with left-sided tumors, the objective response rate was 81%. Disease control rates were 95% in first-line patients and 93% in second-line patients.
The data was presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.
Petosemtamab-related treatment-emergent adverse events led to discontinuation in 2 of 42 patients receiving petosemtamab plus mFOLFOX6 and 1 of 37 patients receiving petosemtamab plus FOLFIRI. Infusion-related reactions occurred in 48% of patients receiving petosemtamab plus FOLFOX and 43% receiving petosemtamab plus FOLFIRI.
The trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had not previously received anti-EGFR therapy. Patients received 1,500 mg of petosemtamab every two weeks plus FOLFOX or FOLFIRI chemotherapy.
Genmab is conducting four Phase 3 trials of petosemtamab, including two in colorectal cancer and two in head and neck squamous cell carcinoma. The company will host an investor update on Wednesday.
Colorectal cancer is the third most commonly diagnosed cancer globally, with an estimated 1.9 million new cases annually, according to the World Health Organization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
e5d145c5c9· 2026-10-25 21:28 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前